StratifiCare, Inc.

StratifiCare, Inc. is a Singapore-based medical technology company established in 2015 with a focus on in-vitro diagnostics (IVD) for personalized medicine. The company was co-founded by CEO Dr. Anthony Chua, who holds a PhD in Virology from the National University of Singapore (NUS) and has a background in high-tech entrepreneurship and involvement in several biotech startups. His expertise in virology and prior contributions to the acquisitions of other biotech firms like Protez Pharmaceuticals by Novartis informed the company's direction.

The firm operates within the clinical diagnostics market, developing and manufacturing assay solutions that assist physicians in making individualized treatment decisions. StratifiCare's business model centers on creating value by improving clinical outcomes and optimizing healthcare resource usage. A significant milestone was achieved in November 2017, when the company received EN ISO 13485:2016 certification, an international quality standard for the design and manufacture of medical devices, ensuring compliance with regulatory bodies like the US FDA and European Union.

StratifiCare's flagship product is StratifiDen™, the world's first prognostic test for Dengue fever. This patented test analyzes a patient's blood sample for specific biomarkers to predict the likelihood of the disease progressing to Severe Dengue. By providing an early assessment, StratifiDen™ enables healthcare providers to triage patients effectively. Patients at high risk for severe complications can be hospitalized promptly for focused care, while those identified as low-risk can be managed through outpatient services. This approach is designed to reduce unnecessary hospitalizations, which preliminary studies suggest could lower the hospitalization burden by up to 67%, thereby preventing healthcare systems in dengue-endemic regions from being overwhelmed and generating significant cost savings. The test is currently delivered as a clinical laboratory test, with plans to develop it into a point-of-care test kit to improve accessibility in remote locations.

Keywords: In-Vitro Diagnostics, personalized medicine, Dengue fever, prognostic test, medical technology, StratifiDen, IVD, clinical diagnostics, biomarker analysis, ISO 13485, virology, healthcare solutions, medical devices, disease prognostication, patient stratification, Anthony Chua, clinical laboratory test, point-of-care testing, severe dengue prediction, healthcare cost reduction